Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus

British Journal of Dermatology

Volumn 153, Issue 3, 2005, Pages 620-625

  Arin, M J ^a   Engert, A ^a   Krieg, T ^a   Hunzelmann, N ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Autoimmune disease; B cell; CD20; Pemphigus; Rituximab; Therapy

Indexed keywords

ANTIHISTAMINIC AGENT; AUTOANTIBODY; AZATHIOPRINE; CD20 ANTIBODY; DESMOGLEIN 1; DESMOGLEIN 3; METHOTREXATE; PARACETAMOL; PREDNISOLONE; RITUXIMAB;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLISTER; CHILL; CLINICAL ARTICLE; COUGHING; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG TOLERABILITY; FACE EDEMA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LYMPHOCYTE DEPLETION; MALE; NAUSEA; PEMPHIGUS; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PEMPHIGUS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 22544433562     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06651.x     Document Type: Article

References (34)

1. Cotell S, Robinson ND, Chan LS. Autoimmune blistering skin diseases. Am J Emerg Med 2000; 18:288-99.
2. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000; 42:422-7.
3. Lin MS, Swartz SJ, Lopez A et al. Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris. J Clin Invest 1997; 99:31-40.
4. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67:869-77.
5. Leyendeckers H, Tasanen K, Bruckner-Tuderman L et al. Memory B cells specific for the NC16A domain of the 180 kDa bullous pemphigoid autoantigen can be detected in peripheral blood of bullous pemphigoid patients and induced in vitro to synthesize autoantibodies. J Invest Dermatol 2003; 120:372-8.
6. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-81.
7. Korman NJ. New and emerging therapies in the treatment of blistering diseases. Dermatol Clin 2000; 18:127-37, ix-x.
8. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22:7359-68.
9. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003; 14:520-35.
10. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000; 27:79-85.
11. Grillo-Lopez AJ, White CA, Dallaire BK et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000; 1:1-9.
12. Quartier P, Brethon B, Philippet P et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001; 358:1511-13.
13. Ratanatharathorn V, Carson E, Reynolds C et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000; 133:275-9.
14. Saleh MN, Gutheil J, Moore M et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000; 27:99-103.
15. Specks U, Fervenza FC, McDonald TJ et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001; 44:2836-40.
16. Lee EJ, Kueck B. Rituxan in the treatment of cold agglutinin disease. Blood 1998; 92:3490-1.
17. Stasi R, Pagano A, Stipa E et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98:952-7.
18. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002; 47:785-8.
19. Goebeler M, Herzog S, Brocker EB et al. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 2003; 149:899-901.
20. Virgolini L, Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case. Haematologica 2003; 88:ELT24.
21. Dupuy A, Viguier M, Bedane C et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004; 140:91-6.
22. Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 2003; 148:602-3.
23. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004; 51:817-19.
24. Anolik JH, Campbell D, Felgar RE et al. The relationship of Fcgamma-RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48:455-9.
25. Amagai M, Hashimoto T, Shimizu N et al. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94:59-67.
26. Hertl M. Humoral and cellular autoimmunity in autoimmune bullous skin disorders. Int Arch Allergy Immunol 2000; 122:91-100.
27. Liu YJ, Banchereau J. Regulation of B-cell commitment to plasma cells or to memory B cells. Semin Immunol 1997; 9:235-40.
28. Zaja F, Iacona I, Masolini P et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87:189-95.
29. Takemura S, Klimiuk PA, Braun A et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001; 167:4710-18.
30. Slifka MK, Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998; 10:252-8.
31. Hoyer BF, Moser K, Hauser AE et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004; 199:1577-84.
32. Bhol K, Natarajan K, Nagarwalla N et al. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci USA 1995; 92:5239-43.
33. Cooper HL, Healy E, Theaker JM et al. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol 2003; 28:366-8.
34. Li N, Aoki V, Hans-Filho G et al. The role of intramolecular epitope spreading in the pathogenesis of endemic pemphigus foliaceus (fogo selvagem). J Exp Med 2003; 197:1501-10.